Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids
- PMID: 11437672
- DOI: 10.2165/00063030-200115010-00002
Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids
Abstract
International guidelines recommend that long-acting beta-agonists should be considered in patients who are symptomatic despite moderate doses of inhaled corticosteroids. When combined with inhaled corticosteroids they improve asthma symptoms and lung function and reduce exacerbations. The evidence suggests that they are well tolerated. However, they are less effective than inhaled corticosteroids as monotherapy and should not be used alone, although the addition of a long-acting beta-agonist may permit a small reduction in the corticosteroid dose. Both salmeterol and formoterol appear equally effective in improving asthma control. Formoterol, however, has a rapid onset of action and is now being promoted for the relief of acute asthma symptoms. Both drugs provide prolonged protection against exercise-induced bronchospasm. However, this effect rapidly diminishes with continuous therapy and if this is the main aim of treatment, intermittent use may be preferable. When compared with alternative treatments, inhaled long-acting beta-agonists are more effective in controlling asthma symptoms than either theophylline or antileukotriene agents. Bambuterol, an oral prodrug of terbutaline, appears to be as effective as the inhaled long-acting beta-agonists and has the advantage of once daily oral administration. However, the inhaled long-acting beta-agonists are less likely to have systemic adverse effects. There are theoretical concerns that regular beta-agonist treatment may lead to tolerance and a failure to respond to emergency asthma treatment. While there is no doubt that tolerance occurs, there is currently little evidence that this is a clinical problem. Insights into pharmacological as well as therapeutic interactions between inhaled corticosteroids and beta-agonists are providing justification for their use in combination. Guidelines for the management of patients with chronic persistent asthma are likely to require modification to reflect these developments.
Similar articles
-
Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?Drugs. 2001;61(3):391-418. doi: 10.2165/00003495-200161030-00007. Drugs. 2001. PMID: 11293649 Review.
-
Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.Eur J Clin Pharmacol. 2009 Sep;65(9):853-71. doi: 10.1007/s00228-009-0682-z. Epub 2009 Jun 26. Eur J Clin Pharmacol. 2009. PMID: 19557399 Review.
-
Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.J Am Osteopath Assoc. 2001 Sep;101(9):526-33. J Am Osteopath Assoc. 2001. PMID: 11575039 Review.
-
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.Drug Saf. 2004;27(10):689-715. doi: 10.2165/00002018-200427100-00001. Drug Saf. 2004. PMID: 15350154 Review.
-
Combination therapy of bronchial asthma.Allergy Asthma Proc. 2001 Jul-Aug;22(4):217-20. Allergy Asthma Proc. 2001. PMID: 11552671 Review.
Cited by
-
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD001281. doi: 10.1002/14651858.CD001281.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636663 Free PMC article.
-
Interactions between corticosteroids and beta2-agonists.Clin Rev Allergy Immunol. 2006 Oct-Dec;31(2-3):231-46. doi: 10.1385/CRIAI:31:2:231. Clin Rev Allergy Immunol. 2006. PMID: 17085796 Review.
-
Current Bronchodilator Responsiveness Criteria Underestimate Asthma in Older Adults.Respir Care. 2020 Aug;65(8):1104-1111. doi: 10.4187/respcare.07132. Epub 2020 Feb 18. Respir Care. 2020. PMID: 32071132 Free PMC article.
-
Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects.Open Respir Med J. 2010 Apr 21;4:48-50. doi: 10.2174/1874306401004010048. Open Respir Med J. 2010. PMID: 20556208 Free PMC article.
-
Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.Br J Pharmacol. 2011 Jun;163(3):521-32. doi: 10.1111/j.1476-5381.2011.01257.x. Br J Pharmacol. 2011. PMID: 21306583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical